Recognition of latest CLL therapies highlights new options for other cancers

Article Type

Changed

Fri, 01/04/2019 - 11:10

Display Headline

Author(s)

Last month, the American Society of Clinical Oncology (ASCO) designated the transformation of treatment for chronic lymphocytic leukemia (CLL) as the cancer Advance of Year.¹ The recognition came after the US Food and Drug Administration approved 4 drugs during 2014 for the treatment of CLL: obinutuzumab and ofatumumab, 2 immunotherapeutic drugs for previously untreated CLL; and ibrutinib and idelalisib, molecularly targeted therapies for treatment-resistant or relapsed CLL. The approvals significantly expand the choice of therapies for patients with the disease, which is the most common form of leukemia in adults, and in doing so, they also stand to improve patient survival and quality of life.

Click on the PDF icon at the top of this introduction to read the full article.

Article PDF

JCSO_Feb_2015_37_Henry.pdf

Issue

The Journal of Community and Supportive Oncology - 13(2)

Publications

The Journal of Community and Supportive Oncology

MDedge Hematology and Oncology

Topics

Leukemia, Myelodysplasia, Transplantation

Page Number

37

Legacy Keywords

chronic lymphocytic leukemia, CLL, obinutuzumab ofatumumab, ibrutinib, idelalisib, leukemia

Sections

From the Editor

Author(s)

David Henry

Author(s)

David Henry

Article PDF

JCSO_Feb_2015_37_Henry.pdf

Article PDF

JCSO_Feb_2015_37_Henry.pdf

Last month, the American Society of Clinical Oncology (ASCO) designated the transformation of treatment for chronic lymphocytic leukemia (CLL) as the cancer Advance of Year.¹ The recognition came after the US Food and Drug Administration approved 4 drugs during 2014 for the treatment of CLL: obinutuzumab and ofatumumab, 2 immunotherapeutic drugs for previously untreated CLL; and ibrutinib and idelalisib, molecularly targeted therapies for treatment-resistant or relapsed CLL. The approvals significantly expand the choice of therapies for patients with the disease, which is the most common form of leukemia in adults, and in doing so, they also stand to improve patient survival and quality of life.

Click on the PDF icon at the top of this introduction to read the full article.

Last month, the American Society of Clinical Oncology (ASCO) designated the transformation of treatment for chronic lymphocytic leukemia (CLL) as the cancer Advance of Year.¹ The recognition came after the US Food and Drug Administration approved 4 drugs during 2014 for the treatment of CLL: obinutuzumab and ofatumumab, 2 immunotherapeutic drugs for previously untreated CLL; and ibrutinib and idelalisib, molecularly targeted therapies for treatment-resistant or relapsed CLL. The approvals significantly expand the choice of therapies for patients with the disease, which is the most common form of leukemia in adults, and in doing so, they also stand to improve patient survival and quality of life.

Click on the PDF icon at the top of this introduction to read the full article.

Issue

The Journal of Community and Supportive Oncology - 13(2)

Issue

The Journal of Community and Supportive Oncology - 13(2)

Page Number

37

Page Number

37

Publications

The Journal of Community and Supportive Oncology

MDedge Hematology and Oncology